Vaccine development: Emergex updates on progress on Flavivirus, Filovirus vaccines
by Press Release from Outbreak News Today on (#3K4VQ)
Emergex Vaccines Holding Limited (Emergex), a private biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today provides an update on its vaccine development pipeline and business. Emergex was established in January 2016 with the primary focus of developing 100% synthetic vaccines, designed to elicit a cytotoxic T-cell response ["]
The post Vaccine development: Emergex updates on progress on Flavivirus, Filovirus vaccines appeared first on Outbreak News Today.